TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05519813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets
Description: Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
Study: NCT06513117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change
Description: healthy conversations to support behaviour change

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary support
Description: Guidance on healthy eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing pattern retraining
Description: guidance on breathing pattern in exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise intervention prescribed to participant fitness level
Study: NCT05896319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area.
Study: NCT05111483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tupler technique
Description: The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre
Study: NCT05598580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosylmethionine
Description: Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
Study: NCT05624827

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing DNA methylation test for predicting prognosis of untreated CIN 2
Description: After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
Study: NCT05419245

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance of the Face
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance of the Face
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance of the Face
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face.

Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance of the Face
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face.
Study: NCT06553365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-159
Description: FCN-159 8mg qd po
Study: NCT06219642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness using virtual reality
Description: In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?
Study: NCT05344014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
Study: NCT06379711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation (tSCS)
Description: Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.
Study: NCT02379299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaCon dual-hormone closed-loop glucose control algorithm
Description: Dual-hormone closed-loop glucose control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DiaCon single-hormone closed-loop glucose control algorithm
Description: Single-hormone closed-loop glucose control
Study: NCT05000944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast omission (BO)
Description: this group will not be provided with a breakfast until lunch time (at 12:30).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early-morning breakfast consumption (EM-BC)
Description: this group will be provided with an early morning breakfast (at 08:30).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mid-morning breakfast consumption (MM-BC)
Description: this group will be provided with a mid (late) morning breakfast (at 10:30).
Study: NCT02205853

Intervention type: OTHER
Group type: OTHER
Intervention: The patient-directed (PD) strategy
Description: The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.

Intervention type: OTHER
Group type: OTHER
Intervention: The multi-faceted (MF) strategy
Description: The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
Study: NCT03997682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hands-Up Program
Description: In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
Study: NCT05591040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
Study: NCT05289258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological treatment
Description: combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).
Description: This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist group
Description: The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
Study: NCT05773313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Open Table
Description: An organization that connects community volunteers to individuals in need to help overcome life's challenges.
Study: NCT06426823

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline / placebo
Description: NaCl (9 mg/ml)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline / placebo
Description: NaCl (9 mg/ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIPR antagonist / study tool
Description: GIP(3-30)NH2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIPR antagonist / study tool
Description: GIP(3-30)NH2
Study: NCT06480942

Intervention type: OTHER
Intervention: Detection of preload responders by a PLR test
Description: Detection of preload dependency by using PLR test and echocardiography

Intervention type: OTHER
Intervention: Detection of preload responders by a PLR test
Description: Detection of preload dependency by using PLR test and echocardiography
Study: NCT06133803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox
Description: A low-molecular-weight heparin, 40mg daily injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg daily tablet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Embryo transfer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo transfer
Description: Embryo transfer
Study: NCT04958122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime 400mg
Description: Oral cefixime 400 mg, one capsule, twice a day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzathine penicillin
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Study: NCT04339920

Intervention type: DIAGNOSTIC_TEST
Intervention: Spermine Measuring Device
Description: The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
Study: NCT05671172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Injection
Description: 20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
Study: NCT05203276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg，SC，Q3W，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 210mg，CIV，Q3W，d1-3
Study: NCT05843110

Intervention type: OTHER
Group type: OTHER
Intervention: Decision-making process
Description: Retrospective evaluation using scales, questionnaires and a semi-structured interview
Study: NCT04703348

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor imagery Questionnaire - Revised Second (MIQ-RS)
Description: Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor imagery Questionnaire - Revised Second (MIQ-RS)
Description: Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor imagery Questionnaire - Revised Second (MIQ-RS)
Description: Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities.
Study: NCT06169735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Portable Handheld Imaging
Description: Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
Study: NCT05253612

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Analog testing conducted by a trained test leader using, ISPOCD test battery
Description: Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Analog testing conducted by a trained test leader using, ISPOCD test battery
Description: Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: self-administered Mindmore digital cognitive screening battery
Description: Cognitive function will be measured by using the Mindmores digital test battery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: self-administered Mindmore digital cognitive screening battery
Description: Cognitive function will be measured by using the Mindmores digital test battery
Study: NCT05032534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cone Small, Qufora A/S
Description: Newly developed cone in a softer material and a design matching the use for transanal irrigation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cone Small, Qufora A/S
Description: Newly developed cone in a softer material and a design matching the use for transanal irrigation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colotip, Coloplast A/S
Description: Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colotip, Coloplast A/S
Description: Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
Study: NCT05157022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Extracorporeal Shock-wave Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Extracorporeal Shock-wave Therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ESWT
Description: Extracorporeal Shock-wave Therapy